I contribute to PhD and Masters programmes in ScHARR including the Wellcome Doctoral Training Centre in Public Health Economics and Decision Science and working on new courses and curriculum development around MSc Health Economics and Decision Modelling, and the online course MSc International Health Technology Assessment and Reimbursement. I undertake substantial applied research/consultancy with healthcare organisations around public health, service development and policy, and with the pharmaceutical industry in the UK and internationally on the cost-effectiveness of interventions. I lead and contribute to the strategic development of research collaborations and programmes within the University, the White Rose, nationally and internationally for funders including NIH (US), MRC, ESRC, NICE, DH and EU. I lead programmes of research on mathematical modelling in health and healthcare focusing on health economics and decision modelling. I am a regular expert on several NICE Scientific Advice Programme panels, providing input to the design of phase III studies from an economic/NICE perspective, usually for global pharmaceutical and device manufacturers. I have been developing and applying modelling in support of healthcare decision-making nationally and internationally, across a large range of diseases, interventions, service planning and policy issues for over 25 years. Together we have now built a large, high-quality team of around 35 or more health economic modelling researchers. I lead a large group of around 35 academic staff, undertaking methodological and applied research and consultancy using mathematical modelling in health and healthcare. Since 1994 I have been leading the modelling team at ScHARR. I studied for BSc Mathematics at Imperial College London and then MSc Operational Research at the London School of Economics before joining the NHS to work in and then lead the Trent Operational Research Unit. I am Professor of Health Economics and Decision Modelling at ScHARR, University of Sheffield, England. Then, the enemy burned down whole cities and shot everyone who stood in its way. Since the War of 1812, there has been only one invasion of the continental U.S. Support for refugee students and scholars VOODOO ECONOMICS: ‘Diary of a Rogue Economist, Why Trump Must Drain the Swamp.Conferences, events, visitor accommodation and weddings.Research centres, institutes and networks. Subject taster sessions for Y12 and Y13 students.Mini Masterclass in Health Research webinars. Policy Research Unit in Economic Methods of Evaluation in Health & Social Care Interventions.Centre for Assistive Technology and Connected Healthcare.Rehabilitation and Assistive Technology.MRC Skills Development Fellowship Programme.That said, if the number of domestic COVID-19 reported cases rise significantly over the next couple of weeks, we would not rule out an intra-meeting cut in March. Tanvee Gupta Jain, economist, UBS Securities India, said: “We now expect the MPC to ease the repo rate by a further 75 bps over the next 12 months (vs 25 bps earlier), with the first cut likely in the April meeting. Upasna Bhardwaj, economist, Kotak Mahindra Bank, said, “With domestic and global growth expected to face downside risks from the spread of COVID-19 and deflationary forces emerging we see room for up to 50bps of rate cut by the MPC, with any further easing contingent on the evolving growth environment.”Īnalysts pointed out that there is limited scope for fiscal action, and therefore, monetary policy will have to step in to support growth. That would only give further licence to the RBI and the MPC to deliver a deep and immediate rate cut,” he said. Further, an FOMC meeting is slotted on March 18 and US rates are seen as heading to 0% soon. “The RBI would need to call for an ad-hoc meeting of the MPC, which the governor could well do. Banks’ credit likely to grow 12%-13% YoY in FY24: SBI report
0 Comments
Leave a Reply. |